Thursday , November 23 2017
Home / Therapies / SGLT-2 Therapy Center (page 18)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Prescription Coverage for SGLT2 inhibitors

Here’s out most recent list of insurance covereage. The cash price for 1 month of Invokana is $315.72. Current actual coverage is: RXE United and other discount cards are approximately $268. PSN Commercial calls it non-formulary and charges a $100 co-pay. AARP-United Health will allow the first fill with a $95 …

Read More »

Dapagliflozin Resubmitted to FDA

The FDA has acknowledged receipt of a resubmission of the new drug application (NDA) for dapagliflozin, an SGLT-2 inhibitor for the treatment of type 2 diabetes…. Astra Zeneca and Bristol-Myers Squibb (BMS) have announced that the agency has issued a new Prescription Drug User Fee Act goal date of January …

Read More »

AACE Presentations of SGLT-2 Inhibitor Data

David Joffe, BSPharm, CDE, Editor-in-chief, Diabetes In Control Lauren Self, University of Florida College of Pharmacy, PharmD Candidate When the finest, most talented endocrinologists get together for a conference, you can bet that there will be a lot of great information on the latest in diabetes care. This year it …

Read More »

SGLT2 Inhibitor Approvals and Updates

Johnson & Johnson’s SGLT2 canagliflozin (Invokana) has just received FDA approval, while Boehringer Ingelheim and Eli Lilly submit their SGLT2 inhibitor (empagliflozin) to the FDA…. U.S. health regulators have approved a new diabetes drug from Johnson & Johnson, making it the first in its class to be approved in the United States. …

Read More »